Protease-activated receptor signalling by coagulation proteases in endothelial cells

Thrombosis and Haemostasis

Volumn 112, Issue 5, 2014, Pages 876-882

  Rezaie, Alireza R ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activated protein C; Protease activated receptor; Signalling; Thrombin

Indexed keywords

ACTIVATED PROTEIN C; ADENOSINE RECEPTOR; BETA ARRESTIN; BLOOD CLOTTING FACTOR; ENDOTHELIAL PROTEIN C RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN C;

ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL (TOPIC); DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; MOLECULAR INTERACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BIOLOGICAL MODEL; CELL MEMBRANE; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION;

ANIMALS; BLOOD COAGULATION FACTORS; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MEMBRANE MICRODOMAINS; MODELS, BIOLOGICAL; NF-KAPPA B; PROTEIN C; PROTEIN CONFORMATION; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION; THROMBIN;

EID: 84908542525     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-02-0167     Document Type: Article

References (78)

1. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-1814.
2. Ruf W, Dorfleutner A, Riewald M. 2003. Specificity of coagulation factor signalling. J Thromb Haemost 2003; 1: 1495-1503.
3. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006; 114: 1070-1077.
4. Antoniak S, Pawlinski R, Mackman N. Protease-activated receptors and myocardial infarction. IUBMB Life 2011; 63: 383-389.
5. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterisation of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998; 95: 6642-6646.
6. Feistritzer C, Lenta R, Riewald M. Protease-activated receptor-1 and-2 can mediate endothelial barrier protection: role in factor Xa signalling. J Thromb Haemost 2005; 3: 2798-2805.
7. Awasthi V, Mandal SK, Papanna V, et al. Modulation of tissue factor-factor VIIa signalling by lipid rafts and caveolae. Arterioscler Thromb Vasc Biol 2007; 27: 1447-1455.
8. Ritchie E, Saka M, MacKenzie C, et al. Cytokine upregulation of proteinase-activated receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells. Br J Pharmacol 2007; 150: 1044-1054.
9. McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signalling by receptor dimerisation. Proc Natl Acad Sci USA 2007; 104: 5662-5667.
10. Bae JS, Yang L, Manithody C, et al. The ligand occupancy of endothelial protein C receptor switches the PAR-1-dependent signalling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007; 110: 3909-3916.
11. McLaughlin JN, Shen L, Holinstat M, et al. Functional selectivity of G protein signalling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 2005; 280: 25048-25059.
12. Mosnier LO, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
13. Esmon CT. Protein C anticoagulant system-anti-inflammatory effects. Semin Immunopathol 2012; 34: 127-132.
14. Weiler H. Multiple receptor-mediated functions of activated protein C. Hamostaseologie 2011; 31: 185-195.
15. Castellino FJ, Ploplis VA. The protein C pathway and pathologic processes. J Thromb Haemost 2009; 7 (Suppl 1): 140-145.
16. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Eng J Med 2001; 344: 699-709.
17. Mitka M. Drug for severe sepsis is withdrawn from market, fails to reduce mortality. J Am Med Assoc 2011; 306: 2439-2440.
18. Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis 2012; 12: 678-686.
19. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106: 2605-2612.
20. Camerer E, Coughlin SR. APC signalling: tickling PAR1 for barrier protection? Blood 2005; 105: 3004-3005.
21. Ossovskaya VS, Bunnett NW. Protease-activated receptors: Contribution to physiology and disease. Physiol Rev 2004; 84: 579-621.
22. Kaplanski G, Marin V, Fabrigoule M, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intracellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 1998; 92: 1259-1267.
23. Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-11203.
24. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280: 17286-17293.
25. Bae JS, Rezaie AR. Thrombin inhibits nuclear factor B and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. Thromb Haemost 2009; 101: 513-520.
26. Hoxie JA, Ahuja M, Belmonte E, et al. Internalisation and recycling of activated thrombin receptors. J Biol Chem 1993; 268: 13756-13763.
27. Hein L, Ishii K, Coughlin SR, et al. Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitisation of a G proteincoupled receptor. J Biol Chem 1994; 269: 27719-27726.
28. Busch C, Cancilla PA, DeBault LE, et al. Use of endothelium cultured on microcarriers as a model for the microcirculation. Lab Invest 1982; 47: 498-504.
29. Ye J, Rezaie AR, Esmon CT. Glycosaminoglycan contributions to both protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93, 97, and 101. J Biol Chem 1994; 269: 17965-17970.
30. Nieman MT, Schmaier AH. Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry 2007; 46: 8603-8610.
31. Bae JS, Yang L, Rezaie AR. Receptors of the protein C activation and activated protein C signalling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 2007; 104: 2867-2872.
32. Bae JS, Yang L, Rezaie AR. Lipid raft localisation regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost 2008; 6: 954-961.
33. Mosnier LO, Sinha RK, Burnier L, et al. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 2012; 120: 5237-5246.
34. Schuepbach RA, Madon J, Ender M, et al. Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects. J Thromb Haemost 2012; 10: 1675-1684.
35. Ludeman MJ, Kataoka H, Srinivasan Y, et al. PAR1 cleavage and signalling in response to activated protein C and thrombin. J Biol Chem 2005; 280: 13122-13128.
36. Toltl LJ, Swystun LL, Pepler L, et al. Protective effects of activated protein C in sepsis. Thromb Haemost 2008; 100: 582-592.
37. Loubele ST, Spronk HM, Ten Cate H. Activated protein C: a promising drug with multiple effects? Mini Rev Med Chem 2009; 9: 620-626.
38. Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-26491.
39. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-1882.
40. Regan LM, Mollica JS, Rezaie AR, et al. The interaction between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C. J Biol Chem 1997; 272: 26279-26284.
41. Feistritzer C, Schuepbach RA, Mosnier LO, et al. Protective signalling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem 2006; 281: 20077-20084.
42. Bae JS, Rezaie AR. Activated protein C inhibits high mobility group box 1 signalling in endothelial cells. Blood 2011; 118: 3952-3959.
43. Rezaie AR. The occupancy of endothelial protein C receptor by its ligand modulates the PAR1-dependent signalling specificity of coagulation proteases. IUBMB Life 2011; 63: 390-396.
44. Lefkowitz RJ, Rajagopal K, Whalen EJ. New roles for -arrestins in cell signalling: Not just for seven-transmembrane receptors. Molecular Cell 2006; 24: 643-652.
45. Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of arrestin-dependent seven transmembrane receptor signalling. Trends Biochem Sci 2011; 36: 457-469.
46. Soh UJ, Trejo J. Activated protein C promotes protease-activated receptor-1 cytoprotective signalling through arrestin and dishevelled-2 scaffolds. Proc Natl Acad Sci USA 2011; 108: E1372-1380.
47. Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 2013; 11 (Suppl 1): 242-253.
48. Schuepbach RA, Feistritzer C, Brass LF, et al. Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood 2008; 111: 2667-2673.
49. Versteeg HH, Schaffner F, Kerver M, et al. Inhibition of tissue factor signalling suppresses tumour growth. Blood 2008; 111: 190-199.
50. Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep 2013; 33: pii: e00064. doi: 10. 1042/BSR20130057.
51. Ahamed J, Ruf W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J Biol Chem 2004; 279: 23038-23044.
52. Ott I, Weigand B, Michl R, et al. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation 2005; 111: 349-355.
53. Ahamed J, Niessen F, Kurokawa T, et al. Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia. Blood 2007; 109: 5251-5259.
54. Pendurthi UR, Rao LV. Factor VIIa interaction with endothelial cells and endothelial cell protein C receptor. Thromb Res 2010; 125 (Suppl 1): S19-22.
55. Ghosh S, Pendurthi UR, Steinoe A, et al. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007; 282: 11849-11857.
56. Sen P, Gopalakrishnan R, Kothari H, et al. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signalling and barrier protection. Blood 2011; 117: 3199-3208.
57. Riewald M, Ruf W. Mechanistic coupling of protease signalling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2001; 98: 7742-7747.
58. Bhattacharjee G, Ahamed J, Pawlinski R, et al. Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1. Circ Res 2008; 102: 457-464.
59. Bukowska A, Zacharias I, Weinert S, et al. Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. Eur J Pharmacol 2013; 718: 114-123.
60. Daubie V, Cauwenberghs S, Senden NH, et al. Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Biochim Biophys Acta 2006; 1763: 860-869.
61. Senden NH, Jeunhomme TM, Heemskerk JW, et al. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 1998; 161: 4318-4824.
62. Rana S, Yang L, Hassanian SM, et al. Determinants of the specificity of proteaseactivated receptors 1 and 2 signalling by factor Xa and thrombin. J Cell Biochem 2012; 113: 977-984.
63. Manithody C, Yang L, Rezaie AR. Identification of exosite residues of factor Xa involved in recognition of PAR-2 on endothelial cells. Biochemistry 2012; 51: 2551-2557.
64. Ambrosini G, Plescia J, Chu KC, et al. Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1. J Biol Chem 1997; 272: 8340-8345.
65. Bae JS, Yang L, Rezaie AR. Factor X/Xa elicits protective signalling responses in endothelial cells directly via PAR-2 and indirectly via endothelial protein C receptor-dependent recruitment of PAR-1. J Biol Chem 2010; 285: 34803-34812.
66. Bae JS, Rezaie AR. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 2008; 100: 101-109.
67. Slofstra SH, Bijlsma MF, Groot AP, et al. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood 2007; 110: 3176-3182.
68. Feistritzer C, Riewald, M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178-3184.
69. Minhas N, Xue M, Fukudome K, et al. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J 2010; 24: 873-881.
70. Bae JS, Rezaie AR. Thrombin upregulates the angiopoietin-Tie2 Axis: endothelial protein C receptor occupancy prevents the thrombin mobilisation of angiopoietin 2 and P-selectin from Weibel-Palade bodies. J Thromb Haemost 2010; 8: 1107-1115.
71. Yang XV, Banerjee Y, Fernández JA, et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signalling in U937 cells. Proc Natl Acad Sci USA 2009; 106: 274-279.
72. Cao C, Gao Y, Li Y, et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010; 120: 1971-1980.
73. Niessen F, Schaffner F, Furlan-Freguia C, et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 2008; 452: 654-658.
74. Guo H, Liu D, Gelbard H, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004; 41: 563-572.
75. Bock F, Shahzad K, Wang H, et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci USA 2013; 110: 648-653.
76. Burnier L, Mosnier LO. Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. Blood 2013; 122: 807-816.
77. Arachiche A, Mumaw MM, de la Fuente M, et al. Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by thrombin. J Biol Chem 2013; 288: 32553-32562.
78. Hassanian SM, Dinarvand P, Rezaie AR. Adenosine Regulates the Proinflammatory Signalling Function of Thrombin in Endothelial Cells. J Cell Physiol 2014; Epub ahead of print.